Drugs / Ventrix Bio Extracellular Matrix
Ventrix Bio Extracellular Matrix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06461676 | Aug 2025 → Sep 2028 expected | hypoplastic left heart syndrome | Emory University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ventrix Bio Extracellular Matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06461676 ↗ |
| Modality | Other / unclassified | “VentriGel, an injectable hydrogel derived from decellularized porcine myocardium” NCT06461676 ↗ |
| Route | Other | “Intramyocardial Injection” NCT06461676 ↗ |